AFFiRiS GmbH

Industry

  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule

Other Names/Subsidiaries

  • AFFiRiS AG
See more in Biomedtracker

Latest on AFFiRiS GmbH

In Vivo

Prevention Better Than Cure? AC Immune's Parkinson’s Vaccine Approach

 
• By Joseph Haas

Lausanne, Switzerland-based AC Immune SA thinks the best potential for treating Parkinson’s disease and other neurodegenerative diseases lies in prevention, using a combination of therapeutic vaccin

Scrip

Blow For Sweden's BioArctic As AbbVie Exits Parkinson's Pact

 
• By Kevin Grogan

Just a couple of months after BioArctic AB trumpeted partner AbbVie Inc. 's plans to advance their Parkinson's drug ABBV-0805 into mid-stage trials this year, the US major has pulled the plug on a

Scrip

Asia Deal Watch: Hanmi Licenses Greater China Rights To Dry AMD Injectable To AffaMed

 
• By Ian Haydock, Anju Ghangurde, Dexter Jie Yan, Jung Won Shin, and Joseph Haas

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AffaMed, Hanmi Ink License Pact To Deve

Scrip

Deal Watch: Seagen Ups Presence In HER2-Positive Cancer Field With RemeGen Deal

 
• By Joseph Haas, Vibha Ravi, and Mandy Jackson

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Seagen, RemeGen Partner Outside Asia, E